Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across�…
B Ricciuti, X Wang, JV Alessi, H Rizvi…�- JAMA�…, 2022 - jamanetwork.com
Importance Although tumor mutation burden (TMB) has been explored as a potential
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about�…
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about�…
Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer
Immune checkpoint inhibitors have shown significant therapeutic responses against tumors
containing increased mutation-associated neoantigen load. We have examined the evolving�…
containing increased mutation-associated neoantigen load. We have examined the evolving�…
Epithelial–mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints�…
Y Lou, L Diao, ERP Cuentas, WL Denning, L Chen…�- Clinical Cancer�…, 2016 - AACR
Purpose: Promising results in the treatment of non–small cell lung cancer (NSCLC) have
been seen with agents targeting immune checkpoints, such as programmed cell death 1 (PD�…
been seen with agents targeting immune checkpoints, such as programmed cell death 1 (PD�…
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell�…
Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint
inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of�…
inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of�…
[HTML][HTML] Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with�…
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with�…
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models
A Martinez-Usatorre, E Kadioglu, G Boivin…�- Science translational�…, 2021 - science.org
Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for
the treatment of non–small cell lung cancer (NSCLC). However, only a minority of patients�…
the treatment of non–small cell lung cancer (NSCLC). However, only a minority of patients�…
[HTML][HTML] Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
KR Voong, J Feliciano, D Becker…�- Annals of translational�…, 2017 - ncbi.nlm.nih.gov
Recently, a firmer understanding of tumor immunology and tumor escape mechanisms has
led to the development of immune checkpoint inhibitors, antibodies against programmed�…
led to the development of immune checkpoint inhibitors, antibodies against programmed�…
Beyond tumor PD-L1: emerging genomic biomarkers for checkpoint inhibitor immunotherapy
Despite the success of immune checkpoint blockade as a strategy for activating an antitumor
immune response and promoting cancer regression, only a subset of patients have durable�…
immune response and promoting cancer regression, only a subset of patients have durable�…
[HTML][HTML] HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L) 1 blockade in advanced non-small�…
Background Immune checkpoint inhibitors (ICIs) have been shown to be beneficial for some
patients with advanced non-small-cell lung cancer (NSCLC). However, the underlying�…
patients with advanced non-small-cell lung cancer (NSCLC). However, the underlying�…
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
DR Gandara, SM Paul, M Kowanetz, E Schleifman…�- Nature medicine, 2018 - nature.com
Although programmed death-ligand 1–programmed death 1 (PD-L1–PD-1) inhibitors are
broadly efficacious, improved outcomes have been observed in patients with high PD-L1�…
broadly efficacious, improved outcomes have been observed in patients with high PD-L1�…